phenol has been researched along with Dwarfism, Pituitary in 5 studies
Dwarfism, Pituitary: A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to provide clinical guidance on dosing and titration of the novel long-acting GH derivative somapacitan based on analyses of somapacitan dose-insulin-like growth factor I (IGF-I) responses in AGHD patients." | 3.11 | Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency. ( Biller, BMK; Hollensen, C; Johannsson, G; Kildemoes, RJ; Rasmussen, MH; Takahashi, Y, 2022) |
| " Pharmacokinetic models were developed for somapacitan and metabolite P1 and used for steady-state assessment in the rat." | 1.72 | Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats. ( Bjelke, M; Helleberg, H; Lindecrona, RH; Thygesen, P, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Helleberg, H | 1 |
| Lindecrona, RH | 1 |
| Thygesen, P | 1 |
| Bjelke, M | 1 |
| Sävendahl, L | 1 |
| Battelino, T | 1 |
| Højby Rasmussen, M | 1 |
| Brod, M | 1 |
| Saenger, P | 1 |
| Horikawa, R | 1 |
| Kildemoes, RJ | 1 |
| Hollensen, C | 1 |
| Biller, BMK | 1 |
| Johannsson, G | 1 |
| Takahashi, Y | 1 |
| Rasmussen, MH | 1 |
| Miller, BS | 2 |
| Yuen, KCJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®[NCT02616562] | Phase 2 | 74 participants (Anticipated) | Interventional | 2016-03-23 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for phenol and Dwarfism, Pituitary
| Article | Year |
|---|---|
Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.
Topics: Adult; Child; Dwarfism, Pituitary; Histidine; Human Growth Hormone; Humans; Insulin-Like Growth Fact | 2022 |
What do we do now that the long-acting growth hormone is here?
Topics: Adult; Child; Dwarfism, Pituitary; Growth Hormone; Histidine; Human Growth Hormone; Humans; Mannitol | 2022 |
2 trials available for phenol and Dwarfism, Pituitary
| Article | Year |
|---|---|
Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
Topics: Body Height; Child; Dwarfism, Pituitary; Growth Hormone; Histidine; Human Growth Hormone; Humans; In | 2022 |
Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
Topics: Adult; Dwarfism, Pituitary; Estrogens; Female; Histidine; Human Growth Hormone; Humans; Insulin-Like | 2022 |
1 other study available for phenol and Dwarfism, Pituitary
| Article | Year |
|---|---|
Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats.
Topics: Animals; Chromatography, High Pressure Liquid; Dwarfism, Pituitary; Female; Growth Hormone; Histidin | 2022 |